17-10078
EZ-Magna ChIP® HT96 Chromatin Immunoprecipitation Kit
Select a Size
£970.00
About This Item
Skip To
technique(s)
immunoprecipitation (IP): suitable
Quality Level
1 of 4
This Item | 17-10077 | 17-10461 | 17-10460 |
|---|---|---|---|
| technique(s) immunoprecipitation (IP): suitable | technique(s) immunoprecipitation (IP): suitable | technique(s) - | technique(s) - |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 100 |
Application
Disclaimer
Features and Benefits
- Complete set of materials for up to 96 ChIP reactions
- Protein A+G bead blend for ChIP with a broader range of antibodies than A or G alone
- Low Chromatin requirements: 10, 000 to 100, 000 cells per reaction
- Includes negative and positive control antibodies and control primer set to simplify validation of experimental procedure
- Optimized streamlined protocol with only a single buffer for sonication, IP, or wash; and protocols for automated liquid handling systemsProtocols for using cells or tissues
- Direct analysis of DNA without additional clean-up steps
- Compatible with ChIPAb+ validated antibody and primer sets
General description
Other Notes
Packaging
Legal Information
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Superior enrichment, low background. With performance proven for both qPCR and ChIP-seq analysis, the Magna ChIP™ HiSens kit may be the only ChIP kit you’ll ever need. Outperforming any competing kit, this revolutionary approach to ChIP enables enrichment from both low and high amounts of input chromatin while also delivering low backgrounds and high signal-to-noise ratios for ultra-sensitive detection.
Magna ChIP™ HT96 Kits for high throughput chromatin immunoprecipitation
Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service